Serum Institute may start clinical trials of Novavax vaccine for Children in July

New Delhi, June 17: Pune-based vaccine manufacturer Serum Institute of India plans to start clinical trials of the Covid-19 vaccine Novavax for children in July, news agency ANI quoted its sources.

Novavax is a protein-based vaccine candidate engineered from the genetic sequence of the first strain of SARS-CoV-2, the virus that causes COVID-19 disease.

Novavax had created flutters earlier this week as it exhibited a 90.4 percent overall efficacy in Phase 3 clinical trials.

NVX-CoV2373 is stored and stable at 2°- 8°C, allowing the use of existing vaccine supply chain channels for its distribution. It is packaged in a ready-to-use liquid formulation in 10-dose vials.

It can also be stored at ordinary refrigerator temperatures, unlike some other vaccines that have strict freezer requirements. To make the vaccine, Novavax injected the virus into moths.